Stocktoria
Enveric Biosciences, Inc. ENVB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-07-21
Enveric Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M |
| SG&A expense | — | — | — | — | $20.5M |
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M |
| Interest expense | — | — | — | $5,249 | $10,316 |
| Income tax | — | $8,930 | $28,913 | -$1.5M | -$7.5M |
| Net income | -$8.8M | -$9.6M | -$17.3M | -$18.5M | -$49.0M |
| EPS (diluted) | $-36.24 | $-228.48 | $-121.29 | $-13.00 | — |
| Operating cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M |
| Free cash flow | — | — | -$14.1M | -$17.7M | -$11.6M |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M |
| Total liabilities | — | — | — | $4.0M | $4.4M |
| Shareholders' equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M |
Source: SEC EDGAR filings · CIK 0000890821 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.